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Objective. To assess the prevalence of prenatal screening and of adverse outcome in high-risk pregnancies due to maternal HIV
infection. Study Design. The prevalence of prenatal screening in 330 pregnancies of HIV-positive women attending the department
for prenatal screening and/or during labour between January 1, 2002 and December 31, 2012, was recorded. Screening results
were compared with the postnatal outcome and maternal morbidity, and mother-to-child transmission (MTCT) was evaluated.
Results. One hundred of 330 women (30.5%) had an early anomaly scan, 252 (74.5%) had a detailed scan at 20–22 weeks, 18 (5.5%)
had a detailed scan prior to birth, and three (0.9%) had an amniocentesis. In seven cases (2.12%), a fetal anomaly was detected
prenatally and confirmed postnatally, while in eight (2.42%) an anomaly was only detected postnatally, even though a prenatal
scan was performed. There were no anomalies in the unscreened group. MTCT occurred in three cases (0.9%) and seven fetal and
neonatal deaths (2.1%) were reported. Conclusion. The overall prevalence of prenatal ultrasound screening in our cohort is 74.5%,
butoftentheopportunityforprenatalultrasonographyinthefirsttrimesterismissed.Ingeneral,theaimshouldbetoofferprenatal
ultrasonography in the first trimester in all pregnancies. This allows early reassurance or if fetal disease is suspected, further steps
can be taken.
1. Introduction
The majority of women living with HIV are in their repro-
ductive years (ages 15–49) [1,2].Thedramaticdecreaseinthe
riskofmother-to-childHIVtransmission(MTCT)isleading
to normality in the lives of couples affected by HIV, who
want own children. In Europe, the reduction in MTCT to less
than 1% is mainly due to highly active antiretroviral therapy
(HAART). Effective HAART is resulting in suppressed viral
load (VL); thus, a vaginal birth can be as safe as a planned
caesarean section [3, 4]. Avoidance of breastfeeding and
postnatal neonatal postexposure prophylaxis (PEP) further
s u p p o r t st h ee ff e c t i v er e d u c t i o ni nM T C T[ 3–5]. Still there
i saf e a ro fh i g h e rp r e g n a n c yc o m p l i c a t i o n si nw o m e nl i v i n g
withHIV[6].Theliteraturesuggeststhatthereisnoincreased
rate of fetal malformations due to the HIV infection or
HAART[6,7].ApregnantwomanwithHIVinfectionusually
has intensified prenatal care including referral for prenatal
ultrasound screening [8].
Prenatalultrasoundscreening is being offered earlier and
earlier [9]. Large studies of noninvasive prenatal screening
havealreadyindicatedthatitwillleadtoadecreaseofinvasive
prenatal screening procedures such as amniocentesis (AC) or
chorionic villi biopsy (CVS) [10]. If invasive prenatal testing2 Infectious Diseases in Obstetrics and Gynecology
T a b l e1 :M a t e r n a la n dn e o n a t a lc h a r a c t e r i s t i c s .
Characteristics
Value
(total pregnancies 𝑛 = 330,
total newborns 𝑛 = 338)
Maternal age at delivery (±SD) 31.05 ± 5.7
Gravidity 𝑁 = 326
1 89 (27.3%)
2 104 (31.9%)
3 71 (21.8%)
4 38 (11.7%)
≥52 4 ( 7 . 2 % )
Parity 𝑁 = 326
11 6 2 ( 4 9 . 7 % )
2 108 (33.1%)
3 36 (11%)
4 12 (3.7%)
≥5 8 (2.4%)
Duration of pregnancy (weeks of
gestation) 𝑁 = 334
24 + 0–33 + 6 32 (9.6%)
34 + 0–36 + 6 90 (26.9%)
>37 + 0 212 (63.5%)
Ethnicity 𝑁 = 283
Caucasian 95 (33.6%)
African 188 (66.4%)
HIV diagnosis during pregnancy 𝑁 = 327
Yes 79 (24.2%)
No 243 (75.8%)
Mode of delivery 𝑁 = 332
Planned caesarean section 257 (77.4%)
Caesarean section in labor 30 (9%)
Emergency caesarean section 1 (0.3%)
Caesarean section after trial of
vaginal birth 13 (3.9%)
Spontaneous vaginal delivery 29 (8.7%)
Unplanned vaginal delivery 1 (0.3%)
Operative vag delivery
(e.g., forceps) 1 (0.3%)
CD4 count at delivery (cells/𝜇L) 𝑁 = 281
<200 30 (10.5%)
200–349 76 (27%)
≥350 175 (62.5%)
Viral load at delivery (copies/mL) 𝑁 = 301
<50 168 (55.8%)
50–399 88 (29.2%)
≥400 45 (15%)
HAART before the beginning of
pregnancy 𝑁 = 289
Yes 181 (62.6%)
No 108 (37.4%)
Table 1: Continued.
Characteristics
Value
(total pregnancies 𝑛 = 330,
total newborns 𝑛 = 338)
HCV (positive anti-HCV test) 𝑁 = 280
Yes 25 (8.9%)
Negative 255 (91.1%)
5-min APGAR 𝑁 = 330
<40
<7 5 (1.5%)
7–10 325 (98.5%)
Arterial cord pH 𝑁 = 327
<7.0 0
7.0-<7.1 2 (0.6%)
7.1-<7.2 16 (4.9%)
≥7.2 309 (94.5%)
Base excess (±SD) 𝑁 = 323
−2.98 ± 2.15
Weight (g) (±SD) 𝑁 = 333
2837 ± 656
Percentile 𝑁 = 335
<10th 30 (9%)
10–90 291 (86.8%)
>90th 14 (4.2%)
Early anomaly scan (11 + 0–14 + 0
weeks of gestation)
𝑁 = 100
30.5%
Nuchal translucency 𝑁=6 7
20.3%
Anomaly/detailed scan 20–22
weeks of gestation
𝑁 = 252
74.5%
Anomaly scan any time later in
pregnancy
𝑁=1 8
5.5%
Fetal/neonatal anomalies in total 𝑁=1 5
4.5%
MTCT in total 𝑁=3
0.9%
MTCT: mother-to-child transmission; SD: standard deviation.
is necessary, it can be done, but in these circumstances,
HAART should be started prior to the procedure to suppress
t h eV Lb e l o wt h el i m i to fd e t e c t i o n .I nt h e s ec a s e sc u r r e n t ,
evidence suggests that MTCT is very unlikely; however,
studies reporting on the risk of MTCT in invasive prenatal
testing are limited due to small study size [11].
HAART is given during pregnancy for two reasons, first
t ow o m e nw i t ha no w ni n d i c a t i o nf o rH A A R T( t h e yr e q u i r e
treatment for their own health) and secondly to pregnant
women starting therapy purely as a prophylactic treatment to
reduce MTCT.
The aim of our study was to investigate if pregnant HIV-
positive women get referred for special prenatal ultrasound
screening services in our tertiary referral center, but also if
a nda twha tpo in tthep r ena talul traso nogra p h yisperf o rmed .
Pregnant HIV-positive women usually have a combinedInfectious Diseases in Obstetrics and Gynecology 3
Table 2: Maternal and neonatal characteristics according to duration of pregnancy.
Duration of pregnancy in weeks
P value
1 24 + 0–33 + 6
𝑁=3 2
34 + 0–36 + 6
𝑁=9 0
37 + 0–42
𝑁 = 212
Maternal age at delivery (±SD) 32.5 ± 5.8 30.2 ± 5.8 31.2 ± 5.6 𝑃 = 0.102
Gravidity 𝑛 = 326 𝑃 > 0.20
1 7 (24.1%) 21 (24.7%) 68 (28.8%)
2 9 (31%) 28 (32.9%) 67 (31.6%)
3 7 (24.1%) 19 (22.4%) 45 (21.2%)
4 3 (10.3%) 9 (10.6%) 26 (12.3%)
>5 3 (10.3%) 8 (10.1%) 13 (10.7%)
Parity 𝑛 = 326 𝑃 > 0.20
1 16 (55.2%) 42 (49.4%) 104 (49.1%)
2 6 (20.7%) 30 (35.3%) 72 (34%)
3 4 (13.8%) 9 (10.6%) 23 (10.8%)
4 0 3 (3.5%) 9 (4.2%)
>5 3 (10.3%) 1 (1.2%) 4 (1.8%)
Ethnicity 𝑛 = 283 𝑃 > 0.20
Caucasian 5 (22.7%) 27 (38.6%) 63 (33%)
African 17 (77.3%) 43 (61.4%) 128 (67%)
HIV diagnosis during pregnancy 𝑛 = 327 𝑃 > 0.20
Yes 9 (30%) 19 (22.1%) 51 (24.2%)
No 21 (70%) 67 (77.9%) 160 (75.88%)
Mode of delivery 𝑛 = 332 𝑃 < 0.001
Planned caesarean section 26 (83.87%) 70 (78.6%) 161 (75.94%)
Caesarean section during labor 5 (16.13%) 15 (16.85%) 10 (4.72%)
Emergency caesarean section 0 0 1 (0.47%)
Caesarean section after trial of vag birth 0 0 13 (6.13%)
Spontaneous vaginal delivery 0 3 (3.37%) 26 (12.26%)
Unplanned vaginal delivery 0 1(1.12%) 0
Instrumental vaginal delivery (e.g., Forceps) 0 0 1 (0.47%)
CD4 count at delivery (cells/𝜇L) 𝑛 = 281 𝑃 = 0.075
<200 2 (8%) 6 (8.3%) 22 (12%)
200–349 12 (48%) 14 (19.4%) 50 (27.2%)
>350 11 (44%) 52 (72.2%) 112 (60.9%)
Viral load at delivery (copies/mL) 𝑛 = 301 𝑃 < 0.001
<50 9 (36%) 27 (34.6%) 132 (66.7%)
50–399 7 (28%) 32 (41%) 49 (24.7%)
≥400 9 (36%) 19 (24.4%) 17 (8.6%)
HAART before beginning of pregnancy 𝑛 = 289 𝑃 > 0.20
Yes 17 (66.7%) 41 (55.4%) 123 (65.4%)
No 10 (33.3%) 33 (44.6%) 65 (34.6%)
HCV (positive anti-HCV test) 𝑛 = 280 𝑃 > 0.20
Yes 2 (8%) 10 (13.2%) 13 (7.3%)
Negative 23 (92%) 66 (86.8%) 166 (92.7%)
5-min APGAR 𝑛 = 330
<4 000 𝑃 < 0.001
<7 5 (17.24%) 0 0
7–10 24 (82.75%) 90 (100%) 211 (100%)4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Continued.
Duration of pregnancy in weeks
P value
1 24 + 0–33 + 6
𝑁=3 2
34 + 0–36 + 6
𝑁=9 0
37 + 0–42
𝑁 = 212
Arterial cord blood levels (𝑛 = 327) 𝑃 = 0.088
<7.0 000
7.0–<7.1 002
7.1–<7.2 3 (10%) 3 (3.4%) 10 (4.83%)
>7.2 27 (90%) 85 (96.6%) 197 (95.17%)
Base excess (𝑛 = 323)( ±SD) 𝑁=2 8
−3.77 ± 2.49
𝑁=8 7
−2.65 ± 2.09
𝑁 = 208
−3.02 ± 2.1
𝑃 = 0.091
Fetal weight (g) (𝑛 = 333)( ±SD)
𝑁=3 2
1573.28 ±
517.98
𝑁=9 0
2634.56 ±
463.12
𝑁 = 211
3115.14 ±
460.06
𝑃 < 0.001
Percentile (𝑛 = 335) 𝑁=3 2 𝑁=9 0 𝑁=2 1 1 𝑃 > 0.20
<10 1 (3.3%) 7 (8.2%) 21 (9.9%)
10–90 28 (84.7%) 80 (88.3%) 183 (86.7%)
>90 3 (10%) 3 (3.5%) 7 (3.3%)
Early anomaly scan (11–14 weeks of gestation) 𝑛 = 100 11 (36.7%) 24 (28.2%) 65 (30.7%) 𝑃 > 0.20
Anomaly scan (second trimester) 𝑛 = 252 26 (81.2%) 68 (75.6%) 158 (74.5%) 𝑃 > 0.20
Anomaly scan at later stage 𝑛=1 8(5.5%) 288 𝑃 > 0.20
Prenatally seen anomalies 𝑛=7(2.1%) 322 𝑃 > 0.20
Postnatal confirmed anomalies
429 𝑃 > 0.20
In total 𝑛=1 5(4.5%)
1P values were calculated without significance correction. Kruskal-Wallis test was used for maternal age, gravidity and parity, APGAR score, apH, vpH, BE,
fetal weight and percentile, fetal length, head circumference, early anomaly scan, anomaly scan. Chi2 test was used for the other characteristics. SD: standard
deviation.
antenatal care in a tertiary referral center and with their own
gynaecologists.
As well as the prevalence of prenatal ultrasound screen-
ing,prenatal,andpostnatalfindingwasrecorded.W ehypoth-
esized that the fetal anomaly rate in women with HIV-
infection is as low as in all other pregnancies (3–5%) [12, 13].
2. Materials and Method
HIV-positive pregnant women who presented in our tertiary
referralcenterbetweenJanuary1,2002andDecember31,2012
were included in this retrospective cohort study.
Only pregnancies ≥24 weeks of gestation were included.
Three categories were used: very preterm delivery (24 + 0 to
33 + 6 weeks of gestation), preterm delivery (34 + 0 to 36 +
6 weeks of gestation), and term delivery (≥37 weeks of
gestation).
All data regarding early prenatal screening (as, e.g.,
nuchal translucency measurements) and fetal anomaly scan
at 20 weeks of gestation or at first presentation in our center
were recorded. Only scans which were performed in our
center were included, reflecting the fact that HIV-positive
pregnant women are high risk pregnancies, and high-risk
pregnancies are referred to a tertiary center or an equivalent
specialized center for prenatal screening [14–17]. An early
anomaly scan was defined as a first trimester scan; in the
studyperiod,thefetalnuchalthicknesswasassessed;aformal
nuchal translucency measurement was included if measured
byappropriatelyqualifiedsonographers.Afetalanomalyscan
wasdefinedasadetailedscaninthesecondtrimester(usually
between20to22weeksofgestation).Allthescansperformed
at a later gestation in our department prior to birth are
recorded separately as late scans in the third trimester. We
collected the abnormal prenatal sonographic findings and
compared prenatal with postnatal detected malformations.
Malformations were any fetal/neonatal disease, which
required either surgery or special pediatric care including
chromosomal anomalies [18]. All cases with an AC, MTCT,
and any intrauterine or postnatal death were evaluated.
Maternal information included age, ethnicity, gestational
age at delivery, gravidity and parity, HAART already before
the pregnancy, VL (copies/mL), CD4 count (cells/𝜇L) prior
to birth, and other risk factors such as coinfection with HCV.
The last recorded VL prior to the delivery was used and
classified in three risk groups. In the study, a VL below 50
is considered as negative/undetectable. The last CD4 count
prior to birth was noted, and again three categories were
u s e d .Th em o d eo fd e l i v e r yw a sc l a s s i fi e da s( 1 )p l a n n e d
caesarean section; (2) in cases of rupture of membranes
and/or contraction it was recorded as elective caesarean
section in labour; (3) emergency caesarean section; (4)
caesarean section after planned vaginal birth; (5) vaginal
birth; (6) unplanned vaginal birth and (7) instrumental
vaginal delivery. In the unit the first planned vaginal birth
was recorded in 2009. Before that time, women were offeredInfectious Diseases in Obstetrics and Gynecology 5
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Figure 1: Percentage of women, who had no early scan and factors
involved (FD = first diagnosis).
electivecaesareansectionataround37+0weeksofgestation
[3, 8, 19]. With evidence for the safety of the vaginal birth
with undetectable VL, the policy in the unit shifted towards
planned vaginal birth, and if caesarean section was offered
in these cases, the delivery was delayed until >37 weeks
of gestation according to the German-Austrian Guidelines
[3, 4, 8]. The following neonatal data were included: APGAR
score, arterial cord pH (apH), cord base excess (BE) and
neonatal weight (stratified according to 10th, 10–90th and
>90th percentile). A weight below the 10th percentile was
considered to be intrauterine growth retardation (IUGR).
Information about scan findings was obtained from the
record of the ultrasound department, and further informa-
tion was collected from maternal case notes, pediatric notes,
and discharge letters.
Ethics approval for the retrospective study was obtained
from the Ethics Committee at the J. W. Goethe University,
Frankfurt (number 30/13).
For categorical variables and nominal variables, fre-
quency tables were used for descriptive statistical analy-
sis. For ordinal and quantitative data, mean and standard
deviation (SD) or percentiles were used. These data were
further analyzed using the Wilcoxon-Mann-Whitney Test,
Kruskal-Wallis Test, Spearman-Correlation, Chi
2-Test, and
Fisher’s Exact Test as appropriate. All tests were 2-sided and
a 𝑃 value below 0.05 was considered statistically significant.
In addition, multivariate logistic regression analysis was
performedtoidentifyfactorsassociatedwithawomanhaving
an early anomaly scan.
Statistical analysis was performed using IBM SPSS 20
statistics software.
3. Results
Overall 330 pregnancies were recorded, with 322 singleton
pregnancies (97.6%) and in eight twin gestations (2.4%).
Table 3: Results of multivariate analysis on factors for a woman to
have an early anomaly scan.
OR 95% CI for OR P value
Ethnicity 2.008 1.155–3.491 0.013
First diagnosis in
present pregnancy 2.085 1.033–4.209 0.040
Gravity 0.767 0.581–1.013 0.062
Parity 1.134 0.756–1.702 0.543
Birth weight 1.000 0.999–1.001 0.710
Gestation at delivery 0.950 0.797–1.133 0.596
OR: odds ratio; CI: confidence interval.
One twin pregnancy was conceived due to IVF with first
diagnosis of the HIV-infection in the early second trimester.
There were 122 preterm deliveries (36.5%) and 90 (26.9%) of
thesewerebetween34and36+6weeksofgestation.Maternal
andneonatalcharacteristicsarepresentedinTable1,stratified
by pregnancy duration in Table 2.
The mean age at presentation was 31.1 ± 5.7 years. Nearly
half of all the women (49.7%) were primiparae. Two thirds
of women (66.4%) were of African ethnicity. In one quarter
of women, the diagnosis HIV of infection occurred in the
pregnancy.Morethanthreequarters257(77.4%)ofthebirths
were elective caesarean section. In 29 cases (8.7%), women
delivered vaginally. The CD4 count (cells/𝜇L) prior to birth
was in the majority of 175 (62.5%) ≥350, in 76 (27%) between
2 0 0a n d3 4 9 ,a n di n3 0( 1 0 . 7 % )<200. The VL (copies/mL)
in most women 168 (55.8%) was suppressed below 50 copies
in 88 (29.2%) 50–399 and in 45 (15%) ≥400. One hundred
and eight women (37.4%) were on no HAART treatment at
the beginning of the pregnancy. In 25 (8.9%), a positive anti-
HCV test was recorded. The average weight of the newborn
was 2837g (±656). Thirty newborns (9%) were classified as
below the 10th percentile [20].
In 100 of the 330 pregnancies (30.5%), we did an early
ultrasound assessment. The nuchal translucency was mea-
s u r e di n6 7( 2 0 . 3 % )o ft h e3 3 0c a s e s( N Tm e d i a n1 . 2 2m m
(range 0.6–3mm)). A multivariate analysis for factors influ-
encing a woman having an early anomaly scan (Table 3)
showed that African ethnicity and first diagnosis of HIV
during the ongoing pregnancy were factors which signifi-
cantlycouldberelatedtonothavingearlyprenatalultrasound
screening (Figure 1).
Invasive testing (AC) was done in three (0.9%) of 330
cases.Onlyonecasewasdoneat25weeksinourdepartment,
and we started HAART and performed the AC after VL was
fully suppressed. The Karyotype was normal. Two cases were
done for advanced maternal age without control of VL and
without specific precautions for example, HAART, and both
revealed a normal Karyotype. In all of three cases, no MTCT
occurred.
In the second trimester in 252 (74.5%) of 330, a detailed
a n o m al ysca na t20 – 22w ee k sw a sd o n e .I n1 8( 5 . 5 % )pa ti e n t s ,
t h es c a nw a sp e r f o r m e di nt h et h i r dt r i m e s t e rd u et ol a t e
presentation in our unit. In Table 4,f e t a la n dn e o n a t a l
malformations as well as chromosomal anomalies are pre-
sented. In seven cases of 330 cases (2.1%), we diagnosed6 Infectious Diseases in Obstetrics and Gynecology
Table 4: Fetal and neonatal malformation/chromosomal anomalies.
HAART Diagnosis
prenatally
Early scan
(first
trimester)
Detailed
scan (second
trimester)
Diagnosis
postnatally
Invasive
testing/Karyotype
Maternal
coinfection
Duration of
pregnancy in
weeks + days
Outcome
CBV TDF
T20 CDH No Yes CDH No HCV 36 + 4
After
operation
alive and well
CBV NVP VSD Yes Yes VSD No HCV HBV 33 + 6 MTCT
CBV NVP
Hydrocephalus,
radial deviation
of hands
No Yes confirmed Yes (normal
Karyotype) No 33 + 1 Died at 1 day
CBV NVP Dandy Walker
malformation No Yes confirmed
Postnatally
unbalanced
translocation
1
No 36 + 1 Died with 3
months
TVD AZT MCDK Potter
2a No Yes confirmed Yes No 37 + 1 Alive and
well
CBV NVP
Heart defect
(ASD and
dextrocardia)
No Yes confirmed No No 37 + 5 Alive and
well
TDF NVP
3TC No Yes Yes Skin tag
(manubrium) No No 37 + 3 Alive and
well
TVD AZT No Yes Yes Skin tag
(finger) No No 36 + 1 Alive and
well
TVD AZT No No Yes Skin tag
(finger) No NO 37 + 714 Alive and
well
TVD NVP No No Yes ASD No No 37 + 1 Alive and
well
TZV TDF
RAL RTV
DRV
No Yes Yes Oesophageal
atresia No
Osophageal
correction
postnatally
33 Alive and
well
AZT TVD
LPV No No Yes VSD No No 41 + 3 Alive and
Well
AZT TVD
SQV RTV No No Yes Trisomy 21 Yes, postnatally No 38 + 0 Alive and
well
LPV/r 3TC
TDF AZT No No Yes
Trisomy 21
VSD and
small ASD
Yes, postnatally No 32 + 4 Alive and
well
TVD
LPV/r No Yes Yes Omphalocele No No 38 + 3 Alive and
well
TVD
LPV/r No Yes Yes Sucking
blister No No 37 + 4 Alive and
well
NVP
TVD No Yes Yes Nevus
sebaceous No No 37 + 2 Alive and
well
146,xy,der(5)t(3;5)(p25.1p15.31).
46,xy,der(5)(5pter>5p15.31:3p25.1>3pter).
CDH:congenitaldiaphragmatichernia;ASD:atrialseptaldefect;VSD:ventricularseptaldefect;MCDK:multicysticdysplastickidneydisease(PotterII);CBV:
zidovudin/lamivudin;TDF:tenofovir;T20:enfuvirtide;NVP:nevirapin;AZT:zidovudin;3TC:lamivudin;RAL:raltegravir;DRV:darunavir;SQV:saquinavir;
RTV: ritonavir; TVD: tenofovir/emtricitabin; LPV/r: lopinavir/ritonavir.
a fetal malformation. There was no apparent coincidence
w i t hH A A R To ra n yo t h e rr e c u r r e n c eo ff e t a lm a l f o r m a t i o n .
Postnatally, all of the seven cases were confirmed, and eight
further malformations and two cases with trisomy 21 were
detected. The chromosomal anomalies were not suspected.
Both women, 33 and 39 years of age, had no early scan or
biochemical screening but a scan in our unit (late in the
second trimester with no anomalies seen). There were three
cases with a skin tag, one nevus sebaceous of the occiput,
a n do n ec a s ew i t has o c a l l e ds u c k i n gb l i s t e ro nt h eh a n d ,
all considered to be minor. Each of these cases had at least
one scan in our department prior to the birth. However, the
sucking blister and the nevus were leading to an upgrade in
neonatalPEPduetobreakingdownofprotectiveskinbarrier,
a n do n en e w b o r np r e s e n t e dw i t has m a l lo m p h a l o c e l ew h i c h
was not seen prior to birth. All of these babies were born byInfectious Diseases in Obstetrics and Gynecology 7
T a b l e5 :N e o n a t a lM o r t a l i t y .
Year Mode of delivery Gestational age
at delivery Death HAART Fetal/neonatal
disease
2003 Planned caesarean
section 33 + 1 First day of
life
CBV NVP EFV
in First
trimester
Complex fetal
anomaly
(hydrocephalus,
radial deviation)
2003 Planned caesarean
section 36 + 1 3m o n t h s C B VN V P
Dandy Walker
malformation
Chromosomal
anomaly
1
2007 Planned caesarean
section (twins) 32 + 2 9m o n t h s A Z TTV D Sudden infant
death
2008
Laparotomy (uterine
rupture) and
hysterectomy due to
placenta percreta
37 + 6 Intrauterine
death
AZT RTV SQV
3TC
Intrauterine
death
2008 Laparotomy and
caesarean section 25 + 2 1d a y K V XN V P
Uterine rupture
after
fibroidectomy
prior to
pregnancy
2009 Planned caesarean
section 29 + 3 4 weeks AZT TVD Volvulus
146,xy,der(5)t(3;5)(p25.1p15.31).
46,xy,der(5)(5pter>5p15.31:3p25.1>3pter).
CBV: zidovudin/lamivudin; NVP: nevirapin; EFV: efavirenz; AZT: zidovudin; TVD: tenofovir/emtricitabin; RTV: ritonavir; SQV: saquinavir; 3TC: lamivudin;
KVX: abacavir/lamivudin.
Table 6: Mother-to-child transmission.
Year Mode of delivery Gestational age at delivery VL at delivery Risk of transmission HAART Coinfection
2003 Planned caesarean section 33 + 6 90 High CBV NVP HCV HBV
2004 Planned caesarean section 36 + 4 1900 Medium CBV NVP No
2010 Planned caesarean section 36 + 3 4830 Medium NVP TVD T20 No
CBV: zidovudine/lamivudin; NVP: nevirapine; TVD, tenofovir/emtricitabin; T20: enfuvirtide.
HCV: hepatitis C; HBV: hepatitis B.
electivecaesareansection.Theoverallfetalmalformationrate
(including the minor anomalies) was 4.5% [18].
InTable5,thefetalandpostnatalmortalitiesarerecorded.
In our cohort, we had six cases of intrauterine or postnatal
loss and all were born by caesarean section. We present in
Table 6 the three cases of MTCT. All of the three newborns
were delivered by caesarean section, and all were preterm
(33 + 6, 36 + 3 and 36 + 4 weeks of gestation). In all cases,
the VL was detectable, all women were on HAART, and one
w o m a nw a sc o i n f e c t e dw i t hH C V .O n ew o m a nh a da l r e a d ya
vertically infected child, and she had a poor compliance.
4. Conclusion
There are conflicting results regarding the risks for HIV-
positive mothers for possible adverse effects in their preg-
nancies [5, 6]. In our study, we confirm the low fetal
malformation rate of 4.5% in women living with HIV. There
aredifferentnationalregisterscollectingdataonHAARTand
pregnancyoutcome(e.g.,APR:AntiviralPregnancyRegistry;
NSHPC:NationalStudyofHIVinPregnancyandChildhood
(UK); ECS: European Collaborative Cohort; EPF—French
PerinatalCohort)[4,21–24].Theseregistersconfirmthesame
malformationrateinwomentakingHAARTasinthegeneral
population (3–5%) [12, 13].
Prenatal screening was found to be successful in diag-
nosing major fetal malformations. The postnatal anomalies
were minor ones (skin tag, sucking blister) or missed due to
minimal extend (omphalocele). The two cases with postnatal
trisomy 21 were missed prenatally but were not seen in
typical screening periods. There were no anomalies in the
unscreened population.
A change in treatment policies is evident over the 11
years of the study, reflected in the changes in delivery mode
over time and the gestational age at delivery [8]. A high
preterm delivery rate is confirmed by other groups [6]. In
our population, 26.9% are late preterm deliveries (34–36 +
6 weeks of gestation) and are mostly iatrogenic due to early
caesarean section as in other studies and in the past [25]. The
updated national German-Austrian Guidelines now delay8 Infectious Diseases in Obstetrics and Gynecology
caesarean section to term in women with suppressed VL [8].
The numbers of women with fully suppressed VL (VL < 50
copies/mL) (𝑃 < 0.001)a n dC D 4c e l l s≥350 (𝑃 > 0.20)p r i o r
to birth increased over the last years.
There are two important screening intervals during the
prenatal period. The first is early screening which should
take place between 11 + 0 and 14 + 0 weeks of gestation
[15]. This early screening was introduced by Nicolaidis in
1 9 9 2a sac o m b i n e dm e t h o do fs c r e e n i n g( i n c l u d i n gu l t r a -
soundscreening and two maternalbiochemical markers: free
human chorionic gonadotropin (free hCG𝗽) and pregnancy-
associated plasma protein A (PAPP-A) [26–28]. In Germany
thistestisnotcoveredbythenationalhealthsystemandthere
for is paid by the woman herself. Usually at that time an early
anomalyultrasoundscancanbeperformed,whichiscovered
by the health system. The second screening interval is the
anomaly scan at 20–22 weeks of gestation [17, 29].
The prevalence of first trimester screening of 97.5% in a
low risk general population has been demonstrated [30].
We demonstrate that prenatal screening is offered and
available, but that the early screening interval is missed, as
only 30.5% women get referred for early anomaly scan. Even
so some women may have chosen not to undergo testing for
ethical and cultural reasons. As a limitation of our data it
could be that the screening which is done at the community-
b a s e dc a r ei sm i s s e d ,b u ta si n d i c a t e du s u a l l y ,i tw a r r a n t s
a referral to a highly qualified and specially trained team
[16, 29].
In our study, population the majority of 188 (66.4%) wo-
men were of African origin, and in 79 (24.2%), the diagnosis
HIV-infection occurred in the pregnancy, both factors were
significantly related to having no early prenatal screening.
Tariq et al. are reporting on late booking for antenatal care
in non-Caucasian women compared with caucasian women
regardless of time of diagnosis of HIV-infection [31].
Th r e ec a s e so fM T C Ta r el o w( 0 . 9 % )a n dc o n fi r m e db y
other groups (reporting MTCT rates of 0.1%–1.3%) [3, 4].
However, looking back in our data, the viral control has
improved dramatically over the last 11 years; in 55.8% of all
pregnancies, the VL is <50.
National health systems vary, and a complete first
trimester screening (with inclusion of biochemical serum
markers) has not been established on a national basis for
high risk pregnancies in some European countries. In our
cohort, two cases of trisomy 21 occurred, and the question
r e m a i n so p e ni ft h e s et w oc a s e sc o u l dh a v eb e e nt r a c e di n
a complete first trimester screening. In one pregnancy, an
AC was performed due to suspected chromosomal anomaly,
whichrevealedanormalkaryotype.Itwasdoneafterstarting
HAART and just after the VL was fully suppressed. Due to
thetimerequiredtoinitiateH AAR Tandtohaveasuppressed
VL in HIV-positive pregnancies, invasive testing will be very
l i k e l yt oh a p p e ni nt h es e c o n dt r i m e s t e rw h i c hw i l lt h e n
raise the difficult ethical questions about late termination of
pregnancywhenanabnormalresultisobtained[32,33].Data
inHIV-positivepregnanciesreportingonACisavailable[32–
34]. First trimester screening (including maternal markers as
free hCG𝗽 a n dP A P P - A )h a sb e e ni n v e s t i g a t e di np r e g n a n t
women living with HIV. Some groups feel that maternal
markers could be less reliable than those in HIV-negative
women [34, 35]. In our study data from 2002 to 2012, in
the first years, the nuchal translucency was assessed but not
formally measured. This could be due to the delay in having
certified specially trained sonographers involved.
In the future, the new methods of chromosome-selective
sequencing of maternal plasma cell-free fetal DNA (cfDNA)
innoninvasiveprenataltesting(NIPT)arevaluableespecially
for our study group due to no risk of MTCT [27]. At present
thisinterestingmethodisnotwidelyavailable,andmoredata
of this new method are needed.
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